FDA 483 OBSERVATION · #224 OF 1,945 MOST-CITED

Valid stability test methods

FDA cited this observation 133 times across 126 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs133
BY FISCAL YEAR
FY20269
FY202525
FY202410
FY20238
FY202210
FY20214
FY20205
FY201920
FY201811
FY201711
FY201620

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 5.2× the rate of the average FDA-cited firm (40.5% vs 7.8%), across 126 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

The written stability program for drug products does not include specific test methods.

AptaPharma Inc. · Pennsauken, New Jersey · Drugs · 2026-08-14

The written stability program for drug products does not include meaningful test methods.

Genuine Virgin Aloe Corp · Anaheim, California · Drugs · 2026-08-14

The written stability program for drug products does not include reliable, meaningful and specific test methods.

Happy Farm Botanicals, Inc. · Hyattsville, Maryland · Drugs · 2026-04-02

The written stability program for drug products does not include reliable, meaningful and specific test methods.

Woodbine Products Company Inc. · Medina, Ohio · Drugs · 2026-02-13

The written stability program for drug products does not include specific test methods.

K.C. Pharmaceuticals, Inc. · Pomona, California · Drugs · 2026-02-13

The written stability program for drug products does not include specific test methods.

Birchwood Laboratories, LLC · Eden Prairie, Minnesota · Drugs · 2026-02-13

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →